Ribavirin Tablets

Not for use as monotherapy. Risk of embryo-fetal toxicity. Females of reproductive potential: obtain negative pregnancy test immediately prior to initiating therapy. Advise females of reproductive potential and males (w. female partners) to use 2 forms of effective contraception during and for 6 months post treatment period. Risk of severe hemolytic anemia. Significant or unstable cardiac disease: not recommended. Assess for underlying cardiac disease prior to initiation. Pre-existing cardiac disease: do ECG prior to therapy and monitor. Do baseline CBC (and at weeks 2 and 4 or more often if needed), WBCs with differential, platelets, blood chemistry, renal function, thyroid, and monthly pregnancy tests (during and for 6 months after treatment). Monitor hepatic function during therapy. Discontinue if cardiovascular status deteriorates, hepatic decompensation, pulmonary disorders, severe hypersensitivity or skin reactions, or pancreatitis occurs. Psychiatric disorders. Organ transplant. Nonresponders to interferon. Maintain adequate hydration. Nursing mothers: not recommended.